|
TCEAL4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.69979999759585E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.98229999970323E-07 |
| Normal-vs-Stage2 |
1.923150E-01 |
| Normal-vs-Stage3 |
1.55940000023946E-07 |
| Normal-vs-Stage4 |
1.3186000002996E-07 |
| Stage1-vs-Stage2 |
1.275200E-03 |
| Stage1-vs-Stage3 |
1.119640E-01 |
| Stage1-vs-Stage4 |
8.816400E-02 |
| Stage2-vs-Stage3 |
2.828400E-04 |
| Stage2-vs-Stage4 |
1.411380E-04 |
| Stage3-vs-Stage4 |
7.079800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.80729997213103E-09 |
| Normal-vs-AfricanAmerican |
1.369810E-02 |
| Normal-vs-Asian |
2.023600E-03 |
| Caucasian-vs-AfricanAmerican |
2.371600E-01 |
| Caucasian-vs-Asian |
1.022610E-01 |
| AfricanAmerican-vs-Asian |
9.785600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.83429999997842E-06 |
| Normal-vs-Female |
8.51589999628644E-08 |
| Male-vs-Female |
9.350000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.21370000003307E-07 |
| Normal-vs-Age(41-60Yrs) |
2.12929999998668E-06 |
| Normal-vs-Age(61-80Yrs) |
1.63662000000064E-05 |
| Normal-vs-Age(81-100Yrs) |
1.757830E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.198000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.760800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.318100E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.714400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.402300E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.324010E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.260200E-03 |
| Classical-VS-Follicular |
8.42030000000049E-05 |
| Classical-VS-Other |
8.900400E-01 |
| Classical-VS-Normal |
5.36269999518169E-08 |
| Tall-VS-Follicular |
1.00499999999837E-06 |
| Tall-VS-Other |
1.703980E-01 |
| Tall-VS-Normal |
1.15449999560369E-08 |
| Follicular-VS-Other |
1.492220E-01 |
| Follicular-VS-Normal |
5.307600E-02 |
| Other-VS-Normal |
2.337500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.99360000000227E-05 |
| Normal-vs-N1 |
7.58010000323495E-08 |
| N0-vs-N1 |
1.212410E-02 |
|
|
